銘利達(301268.SZ):從去年下半年與Rivan持續接觸以來,已在針對部分項目進行報價,以及提供手板件階段,目前雙方溝通情況良好
格隆匯7月11日丨有投資者向銘利達(301268.SZ)提問,“rivan在美國二季度增速非常快,聽説貴公司與其有合作?現在小米的新能源車快研發出來了,公司有計劃進入其產業鏈嗎?”
銘利達回覆稱,從去年下半年與Rivan持續接觸以來,截至目前,公司已在針對部分項目進行報價,以及提供手板件階段,目前雙方溝通情況良好。截至目前,主要溝通項目為儲能領域,後續將在會儲能和新能源車領域全面進行項目的溝通。小米新能源車方面目前暫未有涉及。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.